종합
Japan Times
2026-06-23T00:00:00
Pfizer’s lung cancer drug trial fails to boost survival
원문 보기Patients given the drug, called sigvotatug vedotin, didn't live significantly longer than those given standard therapy.
Patients given the drug, called sigvotatug vedotin, didn't live significantly longer than those given standard therapy.